高血压是心血管疾病重要危险因素,并严重影响心、肾等脏器生理功能.复方降压药采用不同降压机制、通过各组分合理配比,有效控制血压的同时,很好地兼顾治疗其他发病机制诱发的疾病,具有良好的安全性和耐受性.近年来,世界各国在复方降压药物研究开发、临床应用方面取得了很大进展.本文从研发、作用机制、药效学与药动学、临床研究等方面综述了其中代表性的药物进展,包括:苯磺酸氨氯地平/替米沙坦、苯磺酸氨氯地平/缬沙坦、苯磺酸氨氯地平/奥美沙坦酯、苯磺酸氨氯地平/坎地沙坦酯、苯磺酸氨氯地平/氢氯噻嗪/缬沙坦、苯磺酸氨氯地平/氢氯噻嗪/奥美沙坦酯.%Hypertension is a well established risk factor for cardiovascular diseases, which may result in dysfunction of organs such as heart and kidney. The optimal combination of antihypertensive agents will provide a more superior antihypertensive effect than either agent administered as monotherapy, and have different but complementary mechanisms of action as well as a favorable safety and tolerability profile. In recent years, great progresses had been achieved in the worldwide research & development (R&D) and clinical application of compound antihypertensive agents. The R&D, mechanisms of action, pharmacodynamics and pharmacokinetics, clinical studies of compound antihypertensive agents based on CCB/ARB were reviewed in this article. These compound agents include amlodipine besylate and telmisartan, amlodipine besylate and valsartan, amlodipine besylate and olmesartan medoxomil, amlodipine besilate and candesartan cilexetil, amlodipine besylate and hydrochlorothiazide/valsartan , and amlodipine besylate/hydrochlorothiazide/olmesartan medoxomil.
展开▼
